Xin Lang Cai Jing·2025-08-19 07:50Group 1 - Citigroup gives a "Buy" rating to China Biologic Products with a target price raised to HKD 10.5, expecting over 19 new products to be approved in the next three years, many with sales potential exceeding HKD 20 billion [1] - CMB International maintains a "Buy" rating for Sea Group, raising the target price to HKD 28, citing significant profit growth and improved profitability due to strong volume and price increases in the first half of the year [4] - CITIC Securities maintains a "Buy" rating for JD Health, highlighting strong sales growth in pharmaceuticals and health products, and the efficiency improvements from AI medical applications [2] Group 2 - CITIC Securities maintains a "Buy" rating for Netease-S, raising the target price to HKD 240, driven by steady growth in gaming revenue and expectations of new game launches boosting future income [3] - CITIC Securities maintains a "Buy" rating for Leap Motor, raising the target price to HKD 89.2, with expectations of accelerated new car cycles leading to sustained sales and profit growth [5] - CITIC Securities maintains a "Buy" rating for Xtep International, noting robust growth driven by e-commerce and double-digit growth in same-store sales for its subsidiary [6] Group 3 - CICC maintains an "Outperform" rating for Standard Chartered Group, with second-quarter results exceeding expectations, particularly in non-interest income and wealth management [7] - Huaxing Securities maintains a "Buy" rating for Tencent Holdings, raising the target price to HKD 685, citing strong performance across all business segments, particularly in AI-driven advertising revenue [8]